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Keypoints 
 Study question: What impact does a specialist nurse-led telephone assessment/triage 
service (Neurodirect integrated pathway) coupled with standard treatment for significant 
multiple sclerosis (MS) relapses, have on the EQ5D-5L scores as a measure of health 
status? 
 Summary answer: This pathway increases patient health state utility values by 0.15 at 6-
8 weeks follow-up. 
 What is known and what this paper adds: This is the first study of relapses in MS to 
use the EQ5D-5L health status measurement tool and demonstrates the value of the 
NeuroDirect integrated pathway. 
 
 
  
Abstract 
The aim of this study was to assess the impact on health status of a multiple sclerosis (MS) nurse 
specialist telephone assessment/triage (Neurodirect integrated pathway) coupled with standard 
treatment for significant MS relapses. This is an audit-based study of a prospective case series of 
108 patients experiencing relapse symptoms who contacted NeuroDirect, a National Hospital for 
Neurology and Neurosurgery telephone assessment service, in the period February 2012 and 
October 2013. The MS specialist nurse-led teletriage centre applied the EQ5D-5L measure of 
health related quality of life (HRQoL) at the initial assessment and the planned 6-8 weeks 
follow-up. The scores were converted into health state utility values (HSUVs). These showed a 
statistically significant improvement in health status, of 0.15, at 52 days follow-up on average. 
The study demonstrates that an efficient teletriage relapse pathway, as offered by NeuroDirect, 
with standard clinical care has a clear effect on improving HRQoL, as measured for the first time 
by the EQ5D-5L in this population.  
Introduction 
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) 
characterised by demyelination in the brain, spinal cord and optic nerve. Typical presentations 
include visual defects, balance difficulties, limb weakness and sensory change. The disease 
evolution generally involves multiple acute or subacute inflammatory attacks, termed relapses  
(table 1 and annex 1), which last days or weeks and may result in persistent neurological deficits 
(NHS, 2014, Brownlee et al., 2016, Lublin et al., 2014). There are estimated to be 7-8000 
relapses per annum, generating a substantial economic cost (NICE, 2014, Pike et al., 2012). 
Moreover, people with MS (PwMS) suffering relapses not only have to access more healthcare 
resources, but they have a reduced ability to work or participate in family/social activities: all of 
which results in a  lower health-related quality of life (HRQoL) (Jones et al., 2016). 
Relapses in MS 
Definition New symptoms/worsening of existing symptoms that last more than 24 hours in the absence 
of infection or any other cause after a stable period of at least 1 month. 
Symptoms Mobility/balance including falls 
Muscle spasms and stiffness 
Tremor 
Urinary and faecal incontinence  
Sexual dysfunction 
Sensory symptoms and pain 
Speech and swallowing 
Vision disturbances 
Cognitive symptoms 
Depression and anxiety  
Sleep disorders 
Fatigue 
Table 1. Relapses in MS(NICE, 2014) 
Patients with relapses can recover completely or partially, with estimates for the recovery rates 
for mobility related relapses being about 70% at 6 months, while the remaining third either 
require a longer time to recover or have an incomplete recovery (Iuliano et al., 2008). Relapse 
recovery can be facilitated by administration of high-dose corticosteroids (Goodin, 2014), which 
in UK practice are usually intravenous methylprednisolone (IVMP), 1 g/day for three days or 
oral methylprednisolone (OMP), 0.5 g/day for five days (NICE, 2014). Corticosteroid treatment 
improves the speed of recovery, but has no impact on disease progression and frequency of 
relapses (Goodin et al., 2002). Disease progression can be influenced by disease modifying 
therapies (DMTs), particularly  in terms of reduction in relapse frequency (Goodin et al., 2002). 
The relapse service at The National Hospital for Neurology and Neurosurgery (NHNN) 
University College London Hospitals (UCLH) Foundation Trust has previously been described 
(McNicholas et al., 2012) and here we formally evaluate it using a global measure of health 
related quality of life - the EQ5D-5L instrument. The relapse service comprises a number of 
major components: the MS nurse specialist telephone assessment/triage, Neurodirect integrated 
pathway (as described below), clinical evaluation in the clinic, corticosteroid treatment and 
multidisciplinary input from different specialties, such as physiotherapy.  
 
Description of the NeuroDirect pathway 
NeuroDirect is one component of a larger integrated digital care model that supports PwMS to 
access timely advice and treatment interventions. The model includes a telephone triage line 
staffed by MS specialist nurses. Using the service, patients and staff discuss physical, mental, 
and social care needs and agree on tailored care plans (as explained below). The model facilitates 
sharing of information across primary and secondary care organisations, and health and social 
care teams. 
The NeuroDirect electronic clinical assessment tool provides a framework to guide the MS nurse 
through areas of relevant clinical history and importance (for example, it includes assessment of 
‘hidden’ symptoms such as altered mood, abnormal bladder function, pain and fatigue) outlined 
in NICE guidelines (NHS, 2014). It includes ascertainment of possible infection, previous 
relapse history, disease modifying drug use, symptom management medications, steroid use in 
the past (efficacy and side effect profile), the possibility of pregnancy that may impact treatment 
choices, impact of symptoms on psychological wellbeing, daily activity and home life. If the 
patient is concerned that they are experiencing a relapse, the MS specialist nurses conduct a 
relapse specific assessment consisting of symptom status (new/worsening), severity and duration 
of symptoms. The EQ5D-5L questionnaire (Herdman et al., 2011, van Hout et al., 2012) is used 
as an objective measure of quality of life HRQoL as part of the assessment process in the patient 
who are deemed to have a relapse. 
Following the relapse oriented telephone assessment, a joint decision is made with the person 
with MS on how best to proceed. Options include: 1) a period of self-monitoring; 2) a GP visit 
for local assessment and infection screening; or 3) a referral into the relapse clinic for a specialist 
multidisciplinary assessment. Patients referred into the specialist multidisciplinary relapse clinic 
are also booked into a planned telephone follow-up clinic 6-8 weeks later. Those attending the 
relapse clinic would have significant relapses, which although subjective, would typically be a 
moderate-severe motor, sensory or balance disturbance; or a milder impairment which had a 
significant effect on daily work or family function: an example, would be significant 
proprioceptive dysfunction in a woman with a young baby. 
Randomised controlled trials (RCTs) of patients with other chronic conditions, such as chronic 
heart failure, show teletriage assessment to increases quality of life as compared to usual care 
(Scalvini et al., 2005). Teletriage systems are also associated with high patient satisfaction rate, 
55-90% (Turner et al., 2015). 
 
EQ5D-5L Questionnaire 
There are many scores used to assess disability in PwMS, both clinician and patient oriented. 
The most commonly used are the: Extended Disability Status Scale (EDSS), Multiple Sclerosis 
Impact Scale-29 (MSIS-29) and the Multiple Sclerosis Functional Composite (MSFC) (Kurtzke, 
1983, Ontaneda, 2012, Hobart, 2001). However, these are disease-specific, whereas the EQ5D-
5L is a generic tool that can be used to compare disability generated by MS with disability 
generated by other conditions, such as diabetes. Moreover, those described are used to guide 
clinical response rather than HRQoL, so from a health economics perspective, the EQ5D-5L is 
more useful.  
The EQ5D-5L questionnaire is a validated health status measure developed by the EuroQol 
Group used to assess and value the current health of participants (Herdman et al., 2011, van Hout 
et al., 2012). It consists of 5 dimensions that evaluate patient Health Related Quality of Life 
(HRQoL): mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a scale 
from 1 – no problems, to 5 – severe disability (annex 2). In economic studies of the cost utility of 
an intervention the key feature of the EQ5D-5L is the transformation of the health states to a 
single index value which represents health utility producing an anchored score between 0 (Worst 
Possible Health) and 1 (Full health). The health status index used is based on sets of weights that 
have been derived from values from the general population, which implies that these values can 
be associated to a societal valuation of the respondents’ health state.  
  
Methods 
EQ5D-5L Questionnaire and Analysis: 
The EQ5D-5L data was converted to the index score using the EQ5D-5L: Crosswalk Index 
Value Calculator (EURO-QO Version 1.0) – box 1. EQ5D-5L profiles were converted into 
health state utility values (HSUVs) on the day of the first telephone contact and at the 6-8 weeks 
planned follow-up telephone call. HSUVs range from 0 (Worst Possible Health) to 1 (Full 
Health). The values are based on a public database made available by the EuroQuol Group who, 
by using cross-walking technique to produce a preference-based tariff value set evaluated by 
members of the public, patients and health care professionals (Herdman et al., 2011). The 
underlying mechanism for describing change in utility score was derived by subtracting post-
measurement index score from the pre-measurement score to produce a difference as an overall 
measure of the effect of the treatment (HSUV difference = HSUV follow-up – HSUV baseline). 
We evaluated patients’ EQ5D-5L scores at the initial NeuroDirect call and at a planned follow-
up call at 6-8 weeks However, the final cut-off for our study was placed at mean + 2.5xSD, 70 
days, in order to represent 98.5% of the data.  
Microsoft Excel v. 2007 and SPSS v.21 were used for the statistical analysis. Paired t-tests and 
Chi-squared tests were used for numeric data and categorical data, respectively. 
  
Health related quality of 
life (HRQoL) 
Health state utility values 
(HSUV) 
EQ5D-5L profiles 
The value assigned to duration of 
life as modified by the 
impairments, functional states, 
perceptions, and social 
opportunities that are influenced 
by disease, injury, treatment or 
policy. 
Measure of HRQoL based on 
generic questionnaires to describe 
the individual experience of the 
general population or of patients’ 
experience derived from a 
treatment/health intervention. 
Each EQ5D-5L profile is in 
the format 11111-55555 (a 
total of 3125 profiles), from 
best to worst.  
Each EQ5D-5L profile 
corresponds to a HSUV from 1 
(best) to 0 (worst). 
Box 1. Definitions of health related quality of life, health state utility value and EQ5D-5L profile 
(Horsman et al., 2003, Van Hout et al., 2012). 
 
Results 
Between February 2012 and October 2013, 401 PwMS called the NeuroDirect service to report 
symptoms suggestive of relapse. A total of 108 were triaged through the NeuroDirect pathway as 
significant relapses. The EQ5D-5L questionnaire was measured at baseline and at mean 52 days 
(+/-7). Sixpatients with a follow-up later than the chosen cut-off (70 days) were excluded, 
leaving 102 to be evaluated (Figure 1). 98% of patients (100) received IVMP or OMP as relapse 
treatment. 
The mean time from NeuroDirect call to the relapse clinic appointment was 5.4 days (+/- 5.2). 
The demographics are shown in table 2. 
 Figure 1. Study design.  
Variable  
Percentage 
(absolute value) 
Sex Females 74.5% (n=76) 
 Males 25.5% (n=26) 
MS type Relapsing remitting 89.2% (n=91) 
 Secondary progressive 4.9% (n=5) 
 Primary progressive 3.9% (n=4) 
 Clinically isolated syndrome 0.9%  (n=1) 
 Unknown 0.9% (n=1) 
Disease modifying therapy 
(DMT) 
None 55.8% (n=57) 
 Avonex 23.5% (n=24) 
 Copaxone 10.7% (n=11) 
 Rebif 5.8% (n=6) 
 Betaferon 0.9% (n= 1) 
 Azathioprine 0.9% (n=1) 
 Other 1.8% (n=2) 
Urinary tract infection Absent 86.2% (n=88) 
 Present 3.92% (n=14) 
Table 2. Baseline characteristics of the study group. 
  
In addition to a neurologist and MS nursing input, the main other multidisciplinary input was 
physiotherapy (50%)  
 
Figure 2. Additional input recommended for PwMS and an active relapse. OT – occupational 
therapy, PT – physiotherapy
55, 50%
3, 3%
47, 43%
5, 4%
Other input recommended
PT
OT
None
Other
EQ5D-5L 
The overall utility value for the study group at baseline was 0.42 and at 6-8 weeks follow-up 
0.58. There was a 0.15improvement which was statistically significant - p < 0.0001. Figure 3 
shows the individual differences between the utility values at baseline and follow-up. Of note, 83 
(81%) patients had an improvement in health utility values, while only 19 had a decrease. 
 
 
Figure 3. EQ5D-5L utility values at initial call and 6-8 weeks follow-up. HSU difference for 
each patient in the study group, sorted in order of effect. The average improvement was 0.15 
(trendline) *** - p < 0.0001 
 
A breakdown of scores based on the EQ5D-5L items shows a marked improvement in mobility, 
usual activities, pain/discomfort and overall scores. The improvement is less evident in 
anxiety/depression and self-care (Figure4). The overall change in EQ5D-5L scores is driven 
principally by mobility, as most patients had a severe state (score of 5) at baseline, but a 
moderate state (score of 3) at follow-up. This overall trend is recapitulated in each of the 
dimensions with more patients in the normal and mild health states (score 1 and 2) at follow-up 
than at baseline. Simultaneously, the number of patients in the severe and disabling health states 
(scores 4 and 5) decreases at follow-up. 
 
Figure 4. The EQ5D-5L dimensions at baseline (before) and 6-8-weeks follow-up (after) for (a) 
anxiety/depression, (b) self-care, (c) pain/discomfort, (d) mobility and (f) usual activities show 
the percentage of patients in each category (0-5). Patients generally migrate from higher (worse) 
score at baseline (4/5) and demonstrate an improvement, recording less severe scores (1/2) at 
follow up. This is most evident in mobility. 
 There was no significant difference between patients who were on Disease Modifying 
Treatments (DMTs) - HSU score difference 0.16, and those who were DMT naïve – 0.14, 
p=0.68; or between patients who received physiotherapy input - 0.17, and patients who did not - 
0.14, p=0.56. 
 
  
Discussion 
The National Institute for Health and Care Excellence recommends that relapse treatment be 
started within 2 weeks of symptom onset (NICE, 2014). A telephone triage system, such as 
NeuroDirect can be an efficient and effective way of improving specialist coordinated care 
access for PwMS experiencing relapses. The mean time from NeuroDirect call to specialist 
attention was 5 days, well within the 14 days recommended by the NICE guidelines.  
The novelty of this study is the systematic measurement of the EQ5D-5L, pre and post 
assessment and treatment. It is the recommended generic tool to assess health technologies, 
health services used to prevent and treat diseases (NICE, 2008). Indeed, EQ5D-5L been shown 
to be a reliable generic psychometric tool for other medical conditions such as type 2 diabetes 
(Koh et al., 2016, Cheung et al., 2016), and it is currently used as a standard for the development 
of new disease-specific psychometric tools (Hill et al., 2016, Morley et al., 2016). 
EQ5D-5L is the latest version of the most widely accepted HRQoL measure and has only been 
used by 4 studies of UK cohorts of MS patients to date (Wang et al., 2016, Yfantopoulos and 
Chantzaras, 2016, Khan et al., 2016, Shiroiwa et al., 2016, Fogarty et al., 2013, Herdman et al., 
2011). These studies show an inverse correlation (predictive power of regression R2=0.48) 
between the utility values derived from the EQ5D-5L generic health assessment tool and the 
principal MS-specific disability scale used to assess motor impairment in patients with MS, 
EDSS (Hawton and Green, 2016, Fogarty et al., 2013, Orme et al., 2007, Parkin et al., 2000). 
Conversely, one study has questioned the use of generic tools in assessing patients with MS, 
finding a poor correlation between the EQ5D-5L and the patient generated index (PGI) -  an 
individualized measure for quality of life (Kuspinar and Mayo, 2013). However, this study used 
the earlier version, the EQ5D-3L, and only enrolled patients with a mild to moderate motor 
disability, precisely the range for which the EQ5D-5L shows improvement in discrimination 
power. 
Our study shows a statistically significant improvement of 0.15 in HSUV, from 0.42 to 0.58, 
after NeuroDirect teletriage and treatment. Interestingly, cross-sectional studies of MS 
populations in the UK have comparable HSUVs of 0.49 – 0.59 (Orme et al., 2007, Fogarty et al., 
2013). This would suggest that our endpoint, EQ5D-5L, is no different from a general MS 
population. However, these two studies do not distinguish between patients in remission from 
those in relapse. A more accurate comparison of our outcome is to remission HSUVs of 0.604 – 
0.610 in patients who did not experience any relapses in the past 6 months (Parkin et al., 2000, 
Hawton and Green, 2016). This result is in accordance with our remission HSUV of 0.58 at 6-8 
weeks follow-up, and, therefore represents a stable outcome for the following 4 months for these 
MS relapse patients. 
Relapses in MS can be precipitated by infections, such as urinary tract infections (UTIs) 
(Buljevac et al., 2002, Correale et al., 2006) and  a pathway has been described and is followed 
by our service (Phe et al., 2016). In the present study, the rate of UTIs was low (4%), indicating 
that the majority of relapses had not been trigged by an infection.  
This is an example of a service complex intervention, with the main components impacting on 
improvement being time to assessment, relapse severity, corticosteroid use and therapy input. 
These can only be analysed in a qualitative way outside an RCT structure. We demonstrate that 
this model of service (structured teletriage) leads to quick evaluation of the PwMS (52 days) and 
that a therapy intervention (mainly physiotherapy) is used in about half of the relapses. Clearly 
all of these factors, and others, will have an effect on improving the HSU. However, further 
study into the components of teletriage systems is warranted to dissect the role of the MS 
specialist nurse-led assessment and the other factors, such as DMT usage, and subsequent allied 
health professional therapy input. Moreover, the cost-effectiveness of an elective telephone 
assessment system could be directly compared to non-elective admissions to the emergency 
department in this group of patients. 
We also demonstrate an improvement in the individual dimensions of the EQ5D-5L. The greatest 
changes were in mobility, usual activities and pain with significant numbers of patients 
converting from high disability scores to little/no disability scores. The study of EQ5D-5L in MS 
(Fogarty et al., 2013) indicates that it is these three dimensions that are most affected by relapses. 
Of note, anxiety/depression level seems to be the least responsive dimension of the EQ-5D-5L. 
One explanation for this is the high prevalence of background depression and anxiety in PwMS 
with observed prevalences of anxiety being 9-36%, and depression 20% (Marrie et al., 2015, 
Marck et al., 2016) as opposed to rates of 5% and 16%, respectively, in the general population 
(Haussleiter, 2009). We conclude that the higher background levels of anxiety/depression in this 
population are unlikely to reduce with relapse improvement, but are manifestations of a chronic, 
long-term condition. 
 
  
Conclusions 
The present study focuses on a specialist relapse integrated pathway and its impact in managing 
PwMS by streamlining the coordination of care in this subset of patients. We have shown that a 
teletriage relapse pathway for PwMS (NeuroDirect) with all the associated clinical service 
measures (corticosteroid treatment, physiotherapy input and follow-up) improves HRQoL as 
measured for the first time by the global standard EQ5D-5L, from HSUVs of 0.42 to 0.58. We 
also present the changes in the EQ5D-5L individual dimensions in order to gain insight into the 
role disease-specific measurements play in generic HRQoL analysis.  
Key elements of the NeuroDirect teletriage model are now being developed in the scaling-up of 
a larger integrated digital care model across several UK regions. We anticipate that it has the 
potential to improve the health and reduce the cost of care of people with other neurological 
conditions. 
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Annex 1 – NeuroDirect Relapse definition and questionnaire 
The Commissioning Policy for Multiple Sclerosis (England) has defined relapses as clinically 
significant and or clinically disabling to assess the impact of the relapse on the individual.    
 
Clinically significant relapse  
(any of the following) 
Clinically disabling relapse  
(one or more of the following) 
 Any motor relapse 
 Any brainstem relapse 
 A sensory relapse if it leads to functional 
impairment 
 A relapse leading to sphincter dysfunction 
 Optic neuritis 
 Intrusive pain that lasts more than 48 hours 
 
 It affects the patient’s ability to work 
 It affects the patient’s activities of daily living as 
assessed by an appropriate method 
 It affects motor or sensory function sufficiently to 
impair the capacity or reserve to care for themselves or 
others as assessed by an appropriate method 
 The individual needs treatment/hospital admission as a 
result of the relapse 
 
 
 
 
The NeuroDirect team work within the definitions of clinically significant and clinically 
disabling relapses to assess impact and ask a number of  questions including: 
• What symptoms have occurred?  
• Are they new symptoms or a return of old ones?  
• What effect are they having on your daily living?   
• When did they start?  
• Do they fluctuate or are they constant?  
• Do you have any signs of infection?  
• When was last relapse? How was it treated? 
• Are you taking a disease modifying drug?  
• Have you missed any doses?  
• Are you taking any other medication?   
• Are you pregnant or recently given birth (appropriate)? 
• How would you like to manage this episode? 
 
 
 
  
Annex 2 – EQ5D-5L Questionnaire 
 

 
